Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a BRAFV600E mutated high-grade glioma

Dabrafenib plus trametinib is a promising new therapy for patients affected by BRAFV600E-mutant glioma, with high overall response and manageable toxicity. We described a complete and long-lasting response in a case of recurrent anaplastic pleomorphic xanthoastrocytoma CNS WHO-grade 3 BRAFV600E muta...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Barbara Castelli, Marco Tellini, Melina Guidi, Marco Di Nicola, Laura Giunti, Anna Maria Buccoliero, Maria Luigia Censullo, Alessandro Iacono, Isacco Desideri, Lorenzo Genitori, Iacopo Sardi, Carla Fonte
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2024-05-01
Rangatū:	Frontiers in Oncology
Ngā marau:	high-grade glioma MEK inhibitors target therapy dabrafenib trametinib pleomorphic xanthoastrocytoma
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1359093/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!